Breaking News Instant updates and real-time market news.

SYRS

Syros Pharmaceuticals

$10.06

-0.135 (-1.32%)

07:36
08/07/18
08/07
07:36
08/07/18
07:36

Syros Pharmaceuticals reports Q2 EPS (43c), consensus (50c)

Reports Q2 revenue $375,000, consensus $800,000. Cash, cash equivalents and marketable securities as of June 30 were $124.4M, compared with $72M on December 31, 2017.

  • 07

    Aug

  • 14

    Aug

SYRS Syros Pharmaceuticals
$10.06

-0.135 (-1.32%)

10/23/17
ROTH
10/23/17
INITIATION
Target $15
ROTH
Neutral
Syros Pharmaceuticals initiated with a Neutral at Roth Capital
Roth Capital analyst Jotin Marango started Syros Pharmaceuticals with a Neutral rating and $15 price target saying it is maturing into a solid company, but value-driving proof-of-concept may take a little longer.
10/31/17
PIPR
10/31/17
INITIATION
Target $30
PIPR
Overweight
Syros Pharmaceuticals assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff assumed coverage of Syros Pharmaceuticals with an Overweight rating and raised his price target for the shares to $30 from $20. The analyst sees the company creating value by expanding its clinical pipeline and signing new partnerships.
11/01/17
PIPR
11/01/17
NO CHANGE
PIPR
Overweight
Syros trading lower on lack of data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff attributes the pullback today in shares of Syros Pharmaceuticals to the lack of clinical data in the online abstract, but the analyst notes this is just a placeholder. Syros will report Phase II data on SY-1425 monotherapy in biomarker-selected relapsed/refractory Acute Myeloid Leukemia and higher-risk Myelodysplastic Syndromes patients, as well as lower-risk, transfusion-dependent MDS patients in a poster at the American Society of Hematology meeting on December 10, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $30 price target.
07/17/18
PIPR
07/17/18
NO CHANGE
Target $28
PIPR
Overweight
Piper reiterates Overweight on Syros after call with oncologists
After hosting a call with two hematologic oncologists to highlight the unmet need to treat myelodysplastic syndromes and acute myeloid leukemia, Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on shares of Syros Pharmaceuticals with a $28 price target. The analyst notes the company is conducting a Phase II study for SY-1425 in combination with azacitidine or anti-CD38 antibody Darzalex to treat intermediate to high-risk MDS or AML patients with data likely in Q4. Tenthoff remains confident in Syros' combination strategies in the ongoing study.

TODAY'S FREE FLY STORIES

BA

Boeing

$375.05

5.68 (1.54%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Boeing analyst commentary  »

BofA continues to see 6-9…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 24

    Jul

CABO

Cable One

$1,111.46

-18.95 (-1.68%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Cable One analyst commentary  »

Cable One price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$85.74

0.32 (0.37%)

08:01
06/27/19
06/27
08:01
06/27/19
08:01
Recommendations
VF Corp. analyst commentary  »

VF Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

TSLA

Tesla

$219.22

-0.47 (-0.21%)

08:00
06/27/19
06/27
08:00
06/27/19
08:00
Options
Tesla put buyer realizes 36% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$119.01

-1.3 (-1.08%)

07:57
06/27/19
06/27
07:57
06/27/19
07:57
Recommendations
Coupa Software analyst commentary  »

Coupa Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

BB

BlackBerry

$7.55

-0.74 (-8.93%)

07:56
06/27/19
06/27
07:56
06/27/19
07:56
Recommendations
BlackBerry analyst commentary  »

BlackBerry execution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SM

SM Energy

$12.56

0.63 (5.28%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Initiation
SM Energy initiated  »

SM Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

07:55
06/27/19
06/27
07:55
06/27/19
07:55
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

ITRI

Itron

$60.88

0.48 (0.79%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Conference/Events
Itron to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

XEC

Cimarex Energy

$57.17

1.64 (2.95%)

07:53
06/27/19
06/27
07:53
06/27/19
07:53
Initiation
Cimarex Energy initiated  »

Cimarex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

COUP

Coupa Software

$119.01

-1.3 (-1.08%)

07:52
06/27/19
06/27
07:52
06/27/19
07:52
Recommendations
Coupa Software analyst commentary  »

Coupa Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

LECO

Lincoln Electric

$79.77

0.1 (0.13%)

07:52
06/27/19
06/27
07:52
06/27/19
07:52
Downgrade
Lincoln Electric rating change  »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$42.13

0.455 (1.09%)

07:50
06/27/19
06/27
07:50
06/27/19
07:50
Conference/Events
Eaton Vance to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBC

Luther Burbank

$10.33

-0.13 (-1.24%)

07:50
06/27/19
06/27
07:50
06/27/19
07:50
Upgrade
Luther Burbank rating change at Sandler ONeill »

Luther Burbank upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.29

0.54 (2.73%)

07:49
06/27/19
06/27
07:49
06/27/19
07:49
Hot Stocks
Qiwi appoints Vladislav Poshmorga as CFO »

QIWI announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$23.58

-0.24 (-1.01%)

07:48
06/27/19
06/27
07:48
06/27/19
07:48
Upgrade
KB Home rating change  »

KB Home upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIZZ

National Beverage

$42.28

-0.92 (-2.13%)

07:47
06/27/19
06/27
07:47
06/27/19
07:47
Recommendations
National Beverage analyst commentary  »

Guggenheim says National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIVE

Aerohive

$4.44

1.26 (39.62%)

07:46
06/27/19
06/27
07:46
06/27/19
07:46
Downgrade
Aerohive rating change at Craig-Hallum »

Aerohive downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$1.95

0.14 (7.73%)

07:45
06/27/19
06/27
07:45
06/27/19
07:45
Conference/Events
ImmunoGen to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ACRS

Aclaris Therapeutics

$4.45

0.06 (1.37%)

07:43
06/27/19
06/27
07:43
06/27/19
07:43
Downgrade
Aclaris Therapeutics rating change at SVB Leerink »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLS

Apellis

$23.45

-0.38 (-1.59%)

07:43
06/27/19
06/27
07:43
06/27/19
07:43
Hot Stocks
Apellis complete enrollment of Phase 3 APL-2 head-to-head study »

Apellis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

TRIP

TripAdvisor

$44.04

-0.47 (-1.06%)

07:41
06/27/19
06/27
07:41
06/27/19
07:41
Upgrade
TripAdvisor rating change  »

TripAdvisor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRIM

Primoris

$19.95

0.44 (2.26%)

07:40
06/27/19
06/27
07:40
06/27/19
07:40
Hot Stocks
Primoris announces industrial awards valued over $69M »

Primoris Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$23.58

-0.24 (-1.01%)

07:39
06/27/19
06/27
07:39
06/27/19
07:39
Upgrade
KB Home rating change  »

KB Home upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPGN

OpGen

$0.40

-0.0123 (-2.95%)

07:39
06/27/19
06/27
07:39
06/27/19
07:39
Hot Stocks
OpGen says Acuitas panel shows potential to reduce total time to therapy »

OpGen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.